For patients with advanced, radioiodine-refractory differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC) harboring specific genetic alterations such as RET mutations, conventional therapies yield suboptimal outcomes. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.